Nephros Inc (NEPH) 0.2600 $NEPH Nephros Announces

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nephros Inc (NEPH) 0.2600 $NEPH

Nephros Announces Closing of $1.2 Million Note and Warrant Offering
ACCESSWIRE - Thu Jun 09, 3:30PM CDT
RIVER EDGE, NJ / ACCESSWIRE / June 9, 2016 / Nephros, Inc. (OTCQB: NEPH) (the "Company", a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today that it has completed a private placement of unsecured promissory notes and warrants to purchase the Company's common stock resulting in total gross proceeds to the Company of approximately $1.2 million.

Nephros Announces Distribution Agreement with CS Medical, LLC
ACCESSWIRE - Mon May 23, 6:30AM CDT
RIVER EDGE, NJ / ACCESSWIRE / May 23, 2016 / Nephros, Inc. (OTCQB: NEPH), (the "Company" a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, announced today that it has signed a distribution agreement with CS Medical, LLC, a leader in developing, manufacturing, and marketing medical devices designed to provide high-level disinfection of ultrasound Trans-Esophageal Echocardiogram ("TEE" probes.

Nephros Announces Submission of Special 510(k) Application to the FDA for the EndoPur(TM) Ultrafilter
ACCESSWIRE - Thu Apr 21, 6:30AM CDT
RIVER EDGE, NJ / ACCESSWIRE / April 21, 2016 / Nephros, Inc. (OTCQB: NEPH), (the "Company" a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration ("HDF" system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today that it has submitted a Special 510(k) application to the U.S. Food and Drug Administration (FDA) for its EndoPur(TM) ultrafilter designed to provide hemodialysis quality water.

Nephros Receives FDA 510(k) Clearance of S100 Point of Use Filter
ACCESSWIRE - Thu Apr 14, 6:30AM CDT
RIVER EDGE, NJ / ACCESSWIRE / April 14, 2016 / Nephros, Inc. (OTCQB:NEPH), (the "Company" a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration ("HDF" system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration ("FDA" to market its S100 Point of Use filter designed to filter Environmental Protection Agency ("EPA" quality drinking water to retain waterborne bacteria to assist in infection control.

SeeThruEquity Issues Update on Nephros, Inc. (OTCQB: NEPH)
ACCESSWIRE - Wed Apr 06, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / April 6, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update note on Nephros, Inc. (OTCQB: NEPH).

Nephros publishes observational trial of DSU-D in Hospital-Based Dialysis Facility in Nephrology and Dialysis
M2 - Tue Jan 19, 4:50AM CST
Medical device company Nephros (OTCBB:NEPH) said on Monday that data about its DSU-D ultrafilter was published online in Case Reports in Nephrology and Dialysis.

SeeThruEquity Issues Company Update On Nephros, Inc. (OTCQB: NEPH)
ACCESSWIRE - Mon Nov 30, 8:02AM CST
NEW YORK, NY / ACCESSWIRE / November 30, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company update on Nephros, Inc. (OTCQB: NEPH).

Nephros to Present at the LD Micro Main Event
ACCESSWIRE - Tue Nov 24, 8:20AM CST
LOS ANGELES, CA / ACCESSWIRE / November 24, 2015 / Nephros (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, today announced that it will be presenting at the 8th annual LD Micro Main Event on Tuesday, December 1st at 3 PM PST / 6 PM EST. President and CEO and Nephros, Daron Evans, will be giving the presentation and meeting with investors.

Nephros submits S100 Ultrafilter to US FDA for control of infection in medical facilities
M2 - Wed Oct 28, 6:08AM CDT
Medical device company Nephros (OTCBB:NEPH) said on Tuesday that it has submitted the S100 Point of Use filter designed to filter Environmental Protection Agency (EPA) quality drinking water to retain waterborne bacteria to assist in infection control for US Food and Drug Administration (FDA) 510(k) clearance.

Nephros hires Moshe Pinto to board
M2 - Tue Aug 18, 6:04AM CDT
Medical device company Nephros (OTCBB:NEPH) revealed on Monday that Moshe Pinto has been appointed to its board of directors.

Nephros, Inc. Enters Into Purchase Agreement with Lincoln Park Capital Fund, LLC
BusinessWire - Mon Jul 27, 6:30AM CDT
Nephros, Inc. (OTCBB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration ("HDF" system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announced today that it has entered into a purchase agreement with Lincoln Park Capital Fund, LLC ("LPC", a Chicago-based institutional investor. Under the terms of the purchase agreement, over a 36-month term, Nephros will have the right and the sole discretion to sell to LPC up to $10 million worth of shares of Nephros common stock in amounts as set forth in the agreement. Nephros will control the timing and amount of any future investment and LPC will be obligated to make purchases in accordance with the agreement.

SeeThruEquity Initiates Coverage on Nephros, Inc. (OTCBB: NEPH) with Price Target of $1.65
ACCESSWIRE - Thu Jun 04, 7:57AM CDT
NEW YORK, NY / ACCESSWIRE / June 4, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of Nephros, Inc. (OTCQB: NEPH) with Price Target of $1.65.

Nephros posts higher net operating loss of USD806,000 for Q1 2015
M2 - Mon May 18, 5:17AM CDT
Medical device company Nephros (OTCBB:NEPH) disclosed on Friday that it recorded a net operating loss of USD806,000 for the three months ended 31 March 2015.

Nephros expects USD1.2m from private placement of common shares
M2 - Wed May 13, 6:57AM CDT
Medical device company Nephros (OTCBB:NEPH) reported on Tuesday the launch of definitive agreements for the sale of about USD1.2m of its common stock.

Nephros hires Malcolm Persen to board
M2 - Mon May 11, 7:31AM CDT
Medical device company Nephros (OTCBB:NEPH) disclosed on Friday the addition appointment of Malcolm Persen to its board of directors, including chair of the Audit Committee.

Nephros signs HydraGuard military filter licensing agreement with CamelBak
M2 - Thu May 07, 5:15AM CDT
Medical device company Nephros (OTCBB:NEPH) reported on Wednesday that it has granted the exclusive license to its HydraGuard military filter to CamelBak for an undisclosed value.

Nephros Provides Corporate Update
BusinessWire - Mon Dec 08, 3:49PM CST
Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, today provided an update on its operations and strategy.

Nephros Reports Third Quarter 2014 Financial Results and Announces Launch of Rights Offering
PR Newswire - Fri Nov 14, 3:05PM CST
Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, announced today financial results for the three and nine months ended September 30, 2014 and the launch of its previously announced rights offering.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Luca's Campo Morado Denial Makes Guerrero Risk Clear

Updated Category News Views 76

A Dangerous Headline Needs More Than a Quick Rebuttal One ugly allegation can do more damage to a junior miner than a lousy quarter, especially when it involves a mine in Guerrero State and alleged criminal control. Luca Mining has flatly rejected Mexican media reports claiming that its Campo Morado Mine is controlled by a criminal organization. The company says the...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 163

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 160

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 661

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 74

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 67

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 66

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 69

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 265

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Alert: Significant Information Regarding V.F. Corporation

Updated Category News Views 188

Understanding the Current Situation at V.F. Corporation V.F. Corporation, commonly referred to as VFC, is in the spotlight as claims are being investigated by legal teams representing investors. If you are among those impacted, it is essential to be well-informed and proactive in understanding your options. Losses Exceeding $50,000 - Know Your Rights If you have suffered...

Continue Reading
ImmunityBio Soars as Anktiva Fuels 700% Revenue Surge

Updated Category News Views 182

The Market's Wild Ride with ImmunityBio Talk about a rollercoaster! ImmunityBio Inc. is strutting its stuff—stock's up over 55% in just the past month! This kinda takes me back to the dot-com bust: exciting ventures, bold promises, and whoosh—away we fly! Honestly, you can’t ignore that hefty 700% revenue jump. And get this— their leading drug, Anktiva, is really...

Continue Reading
Understanding the Class Action Lawsuit Involving Elevance Health

Updated Category News Views 329

Investigating the Class Action Lawsuit Against Elevance Health Investors should be aware of the ongoing class action lawsuit involving Elevance Health, Inc. (NYSE: ELV). This lawsuit has been initiated to address significant concerns regarding false and misleading statements made by the company. The deadline for potential lead plaintiffs to participate is approaching, and...

Continue Reading
Sprott's Financial Performance for Q2 2025 Highlights Growth

Updated Category News Views 189

Sprott Inc. Financial Performance Report Sprott Inc. (NYSE/TSX: SII) has released its financial results for the second quarter of 2025. The company demonstrated significant growth with the total assets under management (AUM) rising to $40 billion by the end of June 2025. This marks a substantial 14% increase from $35.1 billion in the previous quarter and a compelling 27%...

Continue Reading
Analyzing Market Sentiment on Novo Nordisk Stocks

Updated Category News Views 239

Understanding Novo Nordisk's Stock Market Landscape Novo Nordisk has been experiencing notable fluctuations in its stock market sentiment. Recent reports indicate a decline in the company's short percent of float by 9.09%. With approximately 6.36 million shares sold short, this accounts for merely 0.2% of its available trading shares. Furthermore, based on the current...

Continue Reading